Quarterly report [Sections 13 or 15(d)]

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.25.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 345,253 $ 362,124 $ 1,074,266 $ 1,129,769
OPERATING EXPENSE:        
Medical expense 369,789 401,920 1,093,182 1,149,148
Premium deficiency reserve (23,736) 18,168 (36,665) 15,771
Corporate, general and administrative expense 22,139 27,219 70,433 81,230
Sales and marketing expense 251 134 583 870
Depreciation and amortization 21,033 21,673 63,168 64,905
TOTAL OPERATING EXPENSE 389,476 469,114 1,190,701 1,311,924
OPERATING LOSS (44,223) (106,990) (116,435) (182,155)
OTHER INCOME (EXPENSE):        
Interest expense, net (20,527) (5,647) (39,397) (15,339)
Mark-to-market of stock warrants (2,540) 5,737 2,784 14,626
Other (2,160) 445 (1,259) 1,073
TOTAL OTHER INCOME (EXPENSE) (25,227) 535 (37,872) 360
LOSS BEFORE INCOME TAXES (69,450) (106,455) (154,307) (181,795)
INCOME TAX BENEFIT (PROVISION) (11) 3,605 (3,065) 565
NET LOSS (69,461) (102,850) (157,372) (181,230)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST (37,874) (56,338) (84,943) (103,998)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST $ (31,587) $ (46,512) $ (72,429) $ (77,232)
NET LOSS PER SHARE (Note 9):        
Basic (in dollars per share) $ (9.67) $ (14.36) $ (22.18) $ (12.02)
Diluted (in dollars per share) $ (9.67) $ (15.70) $ (22.18) $ (32.17)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):        
Basic (in shares) 3,268 3,238 3,265 2,786
Diluted (in shares) 3,268 3,294 3,265 2,835
Capitated Revenue [Member]        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 341,555 $ 357,706 $ 1,062,796 $ 1,116,146
Other patient service revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 3,698 $ 4,418 $ 11,470 $ 13,623